chevron_leftBack
As of 13 June 2026, Boundless Bio, Inc. has a market cap of $32.49M USD, ranking #33701 globally and #4743 in the United States.
It ranks #3047 in the Healthcare sector, and #585 in the Biotechnology industry.
Key Stats
Market Cap
$32.49MUSD
Enterprise Value
-$26.28MUSD
EBITDA (TTM)
-$62.3MUSD
Net Income (TTM)
-$58.2MUSD
PB Ratio
0.3
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Zachary Hornby
open_in_new
Employees
28
Founded
2018
IPO
28 Mar 2024
Website
boundlessbio.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 0.7% | -9.8% | 28% | 18% | -2.4% | -1.7% |
News
Loading...
BOLD Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
BOLD
Boundless Bio Inc
ISIN: US10170A1007
Shares Out.:
Shares Outstanding:
22.464M1
Shares Float:
17.219M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
1.45 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Boundless Bio, Inc.
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
561K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
492K%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
85K%
|
-
|
|
NYSE: IQV
|
$26.3B
81K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
77K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
56K%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$47.84B
147K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
138K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
130K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.3B
130K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.11B
86K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
79K%
|
-
|
chevron_leftBack